GlassScriptPhysician profile
Meri J Mccourt
NPI 1780742775
$918.93
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.86 · 2022: $51.53 · 2023: $279 · 2024: $345 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.55 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $193.65 | 2024 | Interstim, Tacker |
| Astellas Pharma US INC | $186.04 | 2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $137.65 | 2023-2025 | Gemtesa |
| Coloplast Corp | $78.64 | 2024-2025 | |
| Abbvie INC. | $77.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.70 | 2022-2023 | Gattex |
| Procept Biorobotics Corporation | $32.92 | 2023 | Aquabeam Robotic System |
| 180 Medical, INC. | $29.14 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $28.86 | 2022-2023 | Exparel |
| Progenics Pharmaceuticals, INC. | $24.41 | 2024 | |
| Accord Healthcare, INC. | $21.87 | 2024 | |
| Merck Sharp & Dohme LLC | $20.88 | 2025 | |
| Myriad Genetic Laboratories, INC. | $17.88 | 2025 | Prolaris |
| Urovant Sciences INC | $17.46 | 2022 | |
| Angiodynamics, INC. | $13.12 | 2024 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meri Mccourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.